PureTech Health plc

Transaction in Own Shares • Nov 22, 2022

National Storage Mechanism | Additional information

RNS Number : 1242H

PureTech Health PLC

22 November 2022

22 November 2022

PureTech Health plc

Transaction in Own Shares

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

Date of purchase:	21 November 2022
Number of ordinary shares purchased:	342
Highest price paid per share:	250.00p
Lowest price paid per share:	249.00p
Volume weighted average price paid per share:	249.58p

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 10,591,626 ordinary shares in treasury and has 278,488,916 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 278,488,916, which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third that is expected to be filed soon for FDA approval, as of the date of PureTech's most recently filed Half-Year Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
21/11/2022	08:51:26	9	250	AQXE	00327210612TRLO1.1.1
21/11/2022	08:51:26	5	250	TRQX	00327210611TRLO1.1.1
21/11/2022	08:51:26	138	250	XLON	00327210610TRLO1.1.1
21/11/2022	08:46:31	9	250	AQXE	00327210085TRLO1.1.1
21/11/2022	08:46:31	18	250	BATE	00327210084TRLO1.1.1
21/11/2022	08:42:39	19	249.5	CHIX	00327209293TRLO1.1.1
21/11/2022	08:39:58	18	249.5	BATE	00327208767TRLO1.1.1
21/11/2022	08:39:46	121	249	XLON	00327208732TRLO1.1.1
21/11/2022	08:39:04	5	249	TRQX	00327208646TRLO1.1.1

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSFLFEDLDLLFIF